Bloomberg News

Fresenius Obtains Reimbursement Approval for Removab in Belgium

October 04, 2011

Oct. 4 (Bloomberg) -- Fresenius Biotech said the Belgian Health Ministry added its trifunctional antibody Removab to the list of reimbursable medications as of Oct. 1. The use of Removab will be reimbursed if the eligible patients also fulfill defined additional clinical inclusion criteria, the company said in an e-mailed statement today.

To contact the editor responsible for this story: Mariajose Vera at mvera1@bloomberg.net


The Good Business Issue
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus